BV-6

Catalog No.S7597 Batch:S759704

Print

Technical Data

Formula

C70H96N10O8.xCF3COOH
Molecular Weight 1205.57 CAS No. 1001600-56-1(freebase)
Solubility (25°C)* In vitro DMSO 100 mg/mL (82.94 mM)
Water 100 mg/mL (82.94 mM)
Ethanol 100 mg/mL (82.94 mM)
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O

Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.

 5.000mg/ml (4.15mM) Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to make it clear; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description BV-6 is a SMAC mimetic, dual cIAP and XIAP inhibitor.
Targets
cIAP [1] XIAP [1]
In vitro

BV6 inhibits the cell viability of HCC193 NSCLC cells with IC50 of 7.2 μM, induces apoptosis in both HCC193 and H460 cell lines, and also significantly enhances the radiosensitivity of these cell lines through activation of cleaved caspase-8 and cleaved caspase-9, respectively. [1]

In immature dendritic cells, this compound treatment results in moderate activation of the classical NF-kB pathway. [2]

Furthermore, it increases CIK cell-mediated lysis of hematological (H9, THP-1, and Tanoue) and solid malignancies (RH1, RH30, and TE671). This chemical also enhances apoptosis of peripheral blood mononuclear cells and most notably has an inhibitory effect on immune cells limiting their cytotoxic potential. [3]
In vivo

BV6 is an IAP antagonist.

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    HCC193 and H460 cells

  • Concentrations

    ~30 μM

  • Incubation Time

    ~48 hours

  • Method

    Cell viability is measured using the CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay kit. 5000 cells/well are seeded into 96-well plates in triplicate. Following adhesion of cells to the wells, increasing concentrations of BV6 are added into different wells. Control groups are exposed to the same concentration of DMSO. The final concentrations of 333 μg/mL MTS and 25 μM PMS are added to each well 24 hours later. After two hours incubation at 37 °C in humidified 5% CO2, plates are read at the absorbance of 490-nm on a microplate reader. Relative cell viability of an individual sample is calculated by normalizing their absorbance to that of the corresponding control. IC50 values are calculated using Prism 5.01. For the TNFα neutralizing antibody assay, cells are exposed to 1 and 5 μM of this compound and the assay is performed 24 hours later. Plates are read at the absorbance of 490-nm on a microplate reader
Animal Study:

[4]
  • Animal Models

    Female BALB/c mice

  • Dosages

    10 mg/kg

  • Administration

    i.p.

References

  • https://pubmed.ncbi.nlm.nih.gov/21760551/
  • https://pubmed.ncbi.nlm.nih.gov/21738708/
  • https://pubmed.ncbi.nlm.nih.gov/25101252/
  • https://pubmed.ncbi.nlm.nih.gov/25376458/

Customer Product Validation

<p>IEC-1 cells were transfected with Per1/2 specific siRNAs or a control siRNA. Afterward, the cells were stimulated with TNFa (0.1 ng/ml under basal conditions) in the presence or absence of BV-6 or were left untreated. Activation of caspase-8 (I) and caspases 3/7 (J ) was assayed. Data are presented as the means±SEM of at least 3 independent experiments. *P≤0.05, **P≤0.01.</p>

, , FASEB J, 2017, 31(11):4707-4719

Treatment of primary CLL cells with the SMAC mimetic BV-6 for 2 hours in presence or absence of 200 ng/mL rhBAFF. Immunoblotting was performed in (H) cytoplasmic and (I) nuclear fractions.

Data from [ , , Clin Cancer Res, 2018, doi:10.1158/1078-0432.CCR-18-1548 ]

Selleck's BV-6 Has Been Cited by 81 Publications

Ferroptosis-activating metabolite acrolein antagonizes necroptosis and anti-cancer therapeutics [ Nat Commun, 2025, 16(1):4919] PubMed: 40425585
Shigella type-III secretion system effectors counteract the induction of host inflammation and cell death [ EMBO J, 2025, 10.1038/s44318-025-00561-7] PubMed: 40931196
The cancer-associated SF3B1K700E spliceosome mutation confers enhanced sensitivity to BV-6-induced cytotoxicity [ Cell Death Dis, 2025, 16(1):476] PubMed: 40595498
Anti-inflammatory mechanism of the MLKL inhibitor necrosulfonamide in LPS- or poly(I:C)-induced neuroinflammation and necroptosis [ Biochem Pharmacol, 2025, 239:117021] PubMed: 40473224
Adenosine triphosphate-binding pocket inhibitor for mixed lineage kinase domain-like protein attenuated alcoholic liver disease via necroptosis-independent pathway [ World J Gastroenterol, 2025, 31(6):96782] PubMed: 39958438
Linear ubiquitination prevents lipodystrophy and obesity-associated metabolic syndrome [ Sci Adv, 2025, 11(38):eadw2539] PubMed: 40961178
Lymph node and tumor-associated PD-L1+ macrophages antagonize dendritic cell vaccines by suppressing CD8+ T cells [ Cell Rep Med, 2024, 5(1):101377] PubMed: 38232703
RIPK1 protects naive and regulatory T cells from TNFR1-induced apoptosis [ Cell Death Differ, 2024, 10.1038/s41418-024-01301-w] PubMed: 38734851
Starvation-induced phosphorylation activates gasdermin A to initiate pyroptosis [ Cell Rep, 2024, 43(9):114728] PubMed: 39264808
The cell cycle inhibitor p21CIP1 is essential for irinotecan-induced senescence and plays a decisive role in re-sensitization of temozolomide-resistant glioblastoma cells to irinotecan [ Biomed Pharmacother, 2024, 181:117634] PubMed: 39489121

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.